Description
LuciRit 50 MG (Ritlecitinib) is a first-in-class selective, irreversible covalent JAK3 and TEC family kinase inhibitor an orally bioavailable, small-molecule targeted immunomodulatory agent that uniquely and covalently binds the catalytic cysteine residue (Cys909) of JAK3 and structurally homologous cysteine residues in TEC family kinases (BTK, ITK, TXK, RLK, and BMX) blocking JAK3/TEC-mediated signalling of the cytokine pathways that drive the autoimmune follicular CD8+ T cell and NKG2D+ innate lymphoid cell attack on hair follicle melanocytes that defines severe alopecia areata supplied as capsules in 50 mg strength in a 28-capsule pack and manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos.
Its active ingredient, ritlecitinib INN, selectively and irreversibly inhibits JAK3 and TEC family kinases with high selectivity over JAK1, JAK2, and TYK2 by forming a covalent bond with the non-conserved cysteine residue (Cys909) present in JAK3 and conserved across TEC family kinases but absent from JAK1, JAK2, and TYK2 catalytic domains, blocking downstream STAT5 phosphorylation and transcription of IFN-gamma-driven cytotoxic CD8+ effector programmes that collapse immune privilege of the hair follicle and cause diffuse scalp, beard, eyebrow, and eyelash hair loss in severe alopecia areata.
In the pivotal Phase 2b/3 ALLEGRO trial, ritlecitinib 50 mg once daily achieved a SALT (Severity of Alopecia Tool) score of 20 or below defined as 80% or greater scalp hair coverage in 23.0% of patients versus 1.6% with placebo at Week 24 (p<0.001), demonstrating statistically significant and clinically meaningful superiority over placebo as the first approved oral JAK3/TEC inhibitor for severe alopecia areata. Searching for LuciRit 50 MG Ritlecitinib? Mediaid Pharmacy lists this product across its dermatology medicines and Lucius Pharmaceuticals portfolios and ships it worldwide.
Basic Product Information of LuciRit 50 MG (Ritlecitinib)
| Brand Name | LuciRit 50 MG (Ritlecitinib) |
| Product Name | LuciRit |
| Generic Name | Ritlecitinib INN |
| Drug Class | First-in-Class Selective Irreversible Covalent JAK3 and TEC Family Kinase Inhibitor; Oral Targeted Immunomodulatory Agent; Alopecia Areata Agent; Dermatology Agent; JAK3/BTK/ITK Inhibitor; CD8+ T Cell Effector Pathway Inhibitor; TEC Kinase Inhibitor |
| Formulation | Capsule (Oral) |
| Available Strengths | 50 mg per capsule |
| Available Pack Size | 28 Capsules per Pack |
| Dosing & Dose Modification | Recommended dose: 50 mg once daily orally, with or without food. No dose titration is required 50 mg once daily is the sole approved therapeutic dose for severe alopecia areata in adults and adolescents aged 12 years and older. Renal impairment: No dose adjustment is required for mild or moderate renal impairment; ritlecitinib has not been adequately studied in severe renal impairment or end-stage renal disease use with caution. Hepatic impairment: No dose adjustment is required for mild hepatic impairment (Child-Pugh A); ritlecitinib is not recommended in moderate or severe hepatic impairment (Child-Pugh B or C). Strong CYP3A inducers (e.g., rifampin, carbamazepine): avoid co-administration concomitant use significantly reduces ritlecitinib exposure and may impair efficacy. Swallow LuciRit capsules whole with water do not open, crush, or chew. No mandatory complete blood count (CBC) or metabolic panel monitoring at baseline is required, though laboratory assessment is recommended in accordance with standard clinical practice for immunomodulatory therapy. |
| Primary Indications | Severe alopecia areata in adults and adolescents 12 years of age and older. LuciRit (Ritlecitinib) is used as a once-daily oral monotherapy. Each treatment decision must account for disease severity, scalp hair coverage area, prior systemic therapy history, infection risk, vaccination status, pregnancy status, and concomitant medications always consult the full prescribing information and the treating dermatologist. |
| Manufacturer | Lucius Pharmaceuticals (Lao) Co., Ltd., Laos |
| Country of Origin | Laos |
| Originator Reference Brand | LITFULO® (ritlecitinib capsules, by Pfizer approved by the FDA in June 2023 for severe alopecia areata in adults and adolescents 12 years and older). LITFULO® contains ritlecitinib INN as the active pharmaceutical ingredient in the same first-in-class selective covalent JAK3/TEC kinase inhibitor drug class. LuciRit is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature (20°C to 25°C; excursions permitted 15°C to 30°C). Keep in the original packaging and protect from moisture. Keep out of the reach of children. |
How LuciRit (Ritlecitinib) Works: First-in-Class Irreversible Covalent JAK3 and TEC Family Kinase Inhibition in Severe Alopecia Areata
Ritlecitinib INN is the world’s first approved oral selective irreversible covalent inhibitor of Janus kinase 3 (JAK3) and TEC family kinases a structurally novel kinase inhibitor class that exploits a non-conserved cysteine residue (Cys909) uniquely present in the kinase domain of JAK3 and conserved across TEC family kinases (BTK, ITK, TXK, RLK, and BMX), but absent from the catalytic domains of JAK1, JAK2, and TYK2. Alopecia areata is an autoimmune disease in which autoreactive CD8+ NKG2D+ T cells and natural killer (NK) cells collapse the immune privilege of the hair follicle anagen bulb by secreting IFN-gamma, IL-15, and IL-2 in a JAK-STAT-dependent manner, driving apoptosis of hair follicle melanocytes and keratinocytes and resulting in non-scarring patchy, diffuse, or total scalp hair loss (alopecia totalis) and, in severe cases, complete body hair loss (alopecia universalis).
JAK3 is selectively expressed on haematopoietic cells and serves as the obligate signalling partner of the common gamma chain (gamma-c, CD132) receptor subunit shared by IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 cytokine receptors precisely the cytokine network that activates, sustains, and amplifies the autoreactive CD8+ T cell effector programme that destroys hair follicle immune privilege in alopecia areata. TEC family kinases, particularly BTK and ITK, are essential downstream mediators of B cell receptor (BTK) and T cell receptor (ITK) signalling in the lymphocyte effector pathways that coordinate the follicular autoimmune attack.
Ritlecitinib exploits a pharmacologically novel covalent inhibition strategy: it irreversibly binds Cys909 in the ATP-binding catalytic domain of JAK3 and structurally homologous cysteine residues in TEC family kinases, forming a permanent covalent adduct that abolishes kinase activity for the lifetime of that enzyme molecule, restoring immune privilege to the hair follicle and enabling anagen (growth phase) re-entry of previously dormant follicles.
The clinical consequence of selective JAK3 and TEC family kinase covalent inhibition in severe alopecia areata is progressive, sustained suppression of the IFN-gamma and IL-15-driven CD8+ cytotoxic T cell programme that collapses hair follicle immune privilege, producing regrowth of scalp hair measurable by the Severity of Alopecia Tool (SALT) score a validated instrument that quantifies scalp hair coverage from 0 (no hair loss) to 100 (complete scalp hair loss). In the pivotal ALLEGRO Phase 2b/3 trial, ritlecitinib 50 mg once daily achieved SALT score of 20 or below (defined as at least 80% scalp hair coverage) in 23.0% of patients versus 1.6% with placebo at Week 24 (p<0.001), with continued improvements in scalp hair regrowth observed through Week 48 in the continuous treatment arm.
The key pharmacological differentiator of ritlecitinib versus pan-JAK inhibitors (ruxolitinib, baricitinib) and reversible JAK1-selective inhibitors is its covalent irreversible mechanism targeting a structurally unique cysteine in JAK3 and TEC kinases: because Cys909 is absent from JAK1, JAK2, and TYK2, ritlecitinib achieves high selectivity for the haematopoietic JAK3/TEC axis, sparing JAK1 and JAK2 signalling pathways involved in erythropoiesis (EPO), thrombopoiesis (TPO), and myelopoiesis, and thereby producing a lymphocyte-targeted rather than pan-immune suppression profile.
Pharmacokinetically, ritlecitinib is absorbed after oral administration, with a terminal elimination half-life consistent with once-daily oral dosing. As a covalent inhibitor, its pharmacodynamic duration is governed by the rate of new enzyme synthesis rather than plasma drug concentration, supporting stable JAK3/TEC inhibition throughout the 24-hour dosing interval. Ritlecitinib is metabolised primarily by CYP3A and to a lesser extent other CYP pathways; it inhibits CYP1A2 and may increase systemic exposure of sensitive CYP1A2 substrates. For the complete range of dermatology medicines at Mediaid Pharmacy, browse the full portfolio for worldwide shipping.
LuciRit 50 MG (Ritlecitinib): Indications, Dosing, and Key Safety Information
| Approved Indications | Severe Alopecia Areata: Treatment of adults and adolescents 12 years of age and older with severe alopecia areata. LuciRit (Ritlecitinib) is administered as oral once-daily monotherapy. |
| Recommended Dose | Adults and adolescents 12 years and older: 50 mg once daily orally, with or without food (1 x LuciRit 50 MG capsule once daily). No dose titration is required. The 50 mg once-daily dose is the sole approved therapeutic dose for ritlecitinib in severe alopecia areata. Swallow LuciRit capsules whole do not open, crush, or chew. Take at the same time each day to maintain consistent plasma concentrations and sustained JAK3/TEC kinase inhibition. |
| Dose Modification | No dose modification is required for mild renal impairment (eGFR 60-89 mL/min/1.73m²) or mild hepatic impairment (Child-Pugh A). Ritlecitinib is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) as pharmacokinetic data in these populations are limited. Ritlecitinib has not been adequately studied in severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease use with caution and under specialist guidance. Avoid co-administration of LuciRit with strong CYP3A inducers (rifampin, carbamazepine, phenytoin) as these markedly reduce ritlecitinib exposure and may substantially compromise clinical efficacy. Monitor sensitive CYP1A2 substrates with narrow therapeutic indices when used concomitantly with LuciRit, as ritlecitinib inhibits CYP1A2. |
| Missed Dose | If a dose of LuciRit is missed, take it as soon as remembered on the same day. If it is not remembered until the next day, skip the missed dose and continue with the next scheduled dose at the regular time. Do not take two doses of LuciRit in one day to make up for a missed dose. |
| Important Warnings and Precautions | Serious Infections: Ritlecitinib may increase the risk of serious bacterial, viral, fungal, and opportunistic infections. Upper respiratory tract infections, herpes zoster, and urinary tract infections have been reported in clinical trials. Evaluate and treat active infections before initiating LuciRit. Interrupt treatment if a patient develops a serious or opportunistic infection. Screen for latent tuberculosis (TB) before initiating LuciRit and treat latent TB before starting therapy.
Malignancy: Ritlecitinib may increase the risk of malignancy. Consider the benefit-risk profile in patients with a prior or current malignancy before initiating LuciRit and refer to current prescribing information for guidance on lymphoma and other malignancy risk. Major Adverse Cardiovascular Events (MACE): Ritlecitinib carries a boxed warning for MACE, consistent with the JAK inhibitor drug class. Use with caution in patients with known cardiovascular risk factors, smoking history, or prior MACE events. Thrombosis: Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported with JAK inhibitor class drugs. Use LuciRit with caution in patients with risk factors for thrombosis and discontinue LuciRit promptly in patients who develop signs and symptoms of thrombosis. Embryo-Fetal Toxicity: Ritlecitinib may cause fetal harm. LuciRit is not recommended in pregnancy. Females of reproductive potential must use effective contraception during LuciRit treatment and for the recommended period after the final dose. A pregnancy test must be performed before initiating therapy. Breastfeeding is not recommended during LuciRit treatment. Live Vaccines: Avoid administration of live or live-attenuated vaccines during LuciRit treatment. Complete all recommended immunisations before starting LuciRit. Inactivated vaccines may be used during treatment. CYP1A2 Drug Interactions: LuciRit inhibits CYP1A2 and may increase systemic exposure of sensitive CYP1A2 substrates (e.g., theophylline, tizanidine). Monitor patients on narrow therapeutic index CYP1A2 substrates concomitantly with LuciRit and reduce CYP1A2 substrate dose as appropriate. Avoid strong CYP3A inducers which substantially reduce ritlecitinib plasma concentrations. Consult the current full prescribing information for the complete and updated safety profile. |
| Common Adverse Reactions | Headache, diarrhea, acne, rash, urticaria, elevated creatine phosphokinase (CPK), nausea, folliculitis, and upper respiratory tract infection. Most adverse reactions with ritlecitinib in the ALLEGRO Phase 2b/3 trial were mild-to-moderate in severity and did not result in treatment discontinuation. Herpes zoster was reported at a low incidence. No clinically significant changes in haemoglobin or platelet count requiring mandatory monitoring were reported as a prescribing condition in the ALLEGRO Phase 2b/3 programme. Always discuss the complete safety profile with the treating dermatologist before and throughout LuciRit treatment. |
| Drug Interactions | Ritlecitinib is metabolised primarily by CYP3A with minor contributions from other CYP pathways. It is an inhibitor of CYP1A2. Strong CYP3A inducers (rifampin, carbamazepine, phenytoin, St. John’s Wort): markedly reduce ritlecitinib AUC avoid co-administration to prevent loss of efficacy. Sensitive CYP1A2 substrates with narrow therapeutic indices (e.g., theophylline, tizanidine, certain antipsychotics): ritlecitinib inhibits CYP1A2 and may increase plasma concentrations monitor for increased substrate effects and toxicity; dose adjustment of the CYP1A2 substrate may be required. Immunosuppressants: Avoid concomitant use of LuciRit with other potent systemic immunosuppressants unless clinically justified and monitored. Disclose all medications, supplements, and immunosuppressants to the treating dermatologist before initiating LuciRit. |
| Renal Impairment | No dose adjustment is required for mild (eGFR 60-89 mL/min/1.73m²) or moderate (eGFR 30-59 mL/min/1.73m²) renal impairment. Ritlecitinib has not been adequately studied in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease use with caution and under the guidance of the treating specialist in this population. |
| Hepatic Impairment | No dose adjustment is required for mild hepatic impairment (Child-Pugh Class A). LuciRit is not recommended in patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment as pharmacokinetic data in these populations are limited. Consult the treating hepatologist and dermatologist for individualised guidance in patients with hepatic comorbidities before initiating LuciRit. |
| Pregnancy & Lactation | Ritlecitinib may cause fetal harm based on animal reproductive toxicity studies, which demonstrated adverse developmental outcomes at clinically relevant exposures. LuciRit is not recommended in pregnancy. Females of reproductive potential must use effective contraception during LuciRit treatment and for the recommended period after the final dose. A pregnancy test must be performed before initiating LuciRit. Breastfeeding is not recommended during LuciRit treatment because of the potential for serious adverse reactions in the breastfed infant. Notify the treating dermatologist immediately if pregnancy occurs during ritlecitinib treatment and discontinue LuciRit promptly. |
Who Should Use LuciRit 50 MG (Ritlecitinib)?
LuciRit 50 MG (Ritlecitinib) is indicated for adults and adolescents aged 12 years and older with severe alopecia areata an autoimmune, non-scarring hair loss disorder characterised at the molecular level by IFN-gamma-dependent collapse of hair follicle immune privilege, CD8+ NKG2D+ T cell cytotoxic attack on hair follicle melanocytes and keratinocytes, and JAK-STAT5 and JAK-STAT3-mediated amplification of the follicular autoimmune cycle that drives progressive, recurrent, and in severe cases permanent-appearing scalp and body hair loss.
First, adults and adolescents 12 years and older with severe alopecia areata defined by SALT score of 50 or above (representing 50% or greater scalp hair loss) and typically including patients with alopecia totalis (complete scalp hair loss, SALT 100) or alopecia universalis (complete scalp and body hair loss) who have failed or are not candidates for intralesional corticosteroid injection, topical immunotherapy (squaric acid dibutyl ester, diphenylcyclopropenone), or systemic corticosteroid pulse therapy constitute the primary indication population for LuciRit. In the pivotal ALLEGRO Phase 2b/3 trial (718 randomised patients), ritlecitinib 50 mg once daily achieved SALT score of 20 or below (at least 80% scalp hair coverage) in 23.0% of patients versus 1.6% with placebo at Week 24 (p<0.001) establishing statistically significant and clinically meaningful superiority over placebo as the first approved oral JAK3/TEC inhibitor for severe alopecia areata.
Second, alopecia areata patients for whom prior systemic therapy with oral corticosteroids, methotrexate, or cyclosporine has proven inadequate, intolerable, or contraindicated and for whom a once-daily oral targeted therapy with a selective JAK3/TEC inhibitor mechanism is preferred over non-selective systemic immunosuppression may receive LuciRit as an evidence-based alternative.
Third, patients with severe alopecia areata and significant quality-of-life burden measured by DLQI or AASIS (Alopecia Areata Impact Scale) particularly those with concurrent anxiety, depression, or social impairment attributable to diffuse scalp hair loss represent a population where ritlecitinib’s demonstrated hair regrowth efficacy through Week 48 provides clinically important psychosocial benefit.
Fourth, adolescent patients aged 12 to 17 years with severe alopecia areata represent a population with particular unmet need, as LuciRit is one of the few systemic alopecia areata agents with a regulatory approval specifically covering the adolescent age group, based on inclusion of adolescent patients in the ALLEGRO Phase 2b/3 programme.
LuciRit is not recommended in pregnancy; not recommended in moderate or severe hepatic impairment; requires co-administration avoidance with strong CYP3A inducers; and necessitates TB screening before initiation. Dermatology centres and specialist hair loss clinics co-sourcing LuciRit alongside other systemic medicines can browse the Mediaid Pharmacy dermatology medicines portfolio for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciRit 50 MG (Ritlecitinib)
Mediaid Pharmacy is a Dhaka-based supplier of specialty dermatology and immunology medicines with worldwide shipping to patients, dermatology clinics, alopecia areata specialist centres, hospital pharmacy departments, hair loss specialist units, and international distributors across all regions. LuciRit 50 MG (Ritlecitinib), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is supplied as 28 capsules per pack in 50 mg strength delivering the full approved therapeutic dose for four weeks of treatment per pack with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. The 28-capsule pack format of LuciRit aligns directly with the once-daily, fixed-dose 50 mg regimen for ritlecitinib, simplifying procurement planning for dermatology programmes and individual patients requiring continuous therapy.
Alopecia areata specialist centres, dermatology programmes managing severe hair loss, hair transplant and trichology units considering medical pre-treatment, hospital pharmacy departments co-sourcing oral targeted therapies, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding LuciRit Ritlecitinib stock availability, current pricing, and international delivery timelines to their country. Procurement teams co-sourcing LuciRit with other specialty dermatology or systemic immunomodulatory medicines can browse the complete Mediaid Pharmacy dermatology medicines collection and the Lucius Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose LuciRit 50 MG (Ritlecitinib) from Mediaid Pharmacy?
LuciRit 50 MG (Ritlecitinib) delivers the world’s first approved oral selective covalent JAK3 and TEC family kinase inhibitor for severe alopecia areata a first-in-class irreversible kinase inhibitor backed by the landmark Phase 2b/3 ALLEGRO trial that establishes ritlecitinib as a clinically effective oral targeted therapy with a selectivity-driven mechanism that spares JAK1, JAK2, and TYK2 pathways associated with haematopoietic, metabolic, and broader immune effects observed with pan-JAK inhibitors. In the ALLEGRO Phase 2b/3 trial (718 randomised patients), ritlecitinib 50 mg once daily achieved SALT score of 20 or below (at least 80% scalp hair coverage) in 23.0% versus 1.6% placebo (p<0.001) at Week 24 representing the first successful Phase 2b/3 trial of an oral targeted therapy in severe alopecia areata to qualify a molecule for FDA approval (June 2023). Meaningful scalp hair regrowth, including SALT score of 10 or below in a subset of patients (representing 90% or greater hair coverage), and continued improvement in eyebrow and eyelash regrowth were observed in the continuous ritlecitinib arm through Week 48.
Ritlecitinib’s covalent irreversible JAK3/TEC kinase inhibition mechanism is fundamentally distinct from both reversible JAK1/2-selective inhibitors (baricitinib, upadacitinib) and pan-JAK inhibitors (ruxolitinib, tofacitinib) achieving sustained JAK3 and TEC kinase pathway blockade for the full enzyme synthesis cycle rather than only during peak drug plasma concentration, targeting the haematopoietic and lymphocyte-specific cytokine network that drives alopecia areata follicular autoimmunity with greater selectivity over erythropoietic and metabolic JAK pathways. The 28-capsule monthly pack of LuciRit precisely matching the once-daily fixed-dose 50 mg regimen with no titration required simplifies dispensing, patient counselling, and procurement for alopecia areata programmes worldwide.
LuciRit is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka. To source additional Lucius Pharmaceuticals dermatology and specialty medicines, visit the Mediaid Pharmacy Lucius Pharmaceuticals medicines section and the dermatology medicines portfolio, and contact the team for a personalized quotation.
Frequently Asked Questions About LuciRit 50 MG (Ritlecitinib)
What is LuciRit 50 MG (Ritlecitinib) used for?
LuciRit 50 MG (Ritlecitinib) is the world’s first approved oral selective covalent JAK3 and TEC family kinase inhibitor, used for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. LuciRit selectively and irreversibly inhibits JAK3 and TEC family kinases (BTK, ITK, TXK, RLK, BMX) by covalently binding the non-conserved cysteine residue (Cys909) in JAK3 and homologous cysteines in TEC kinases, blocking the IFN-gamma and IL-15-driven cytotoxic CD8+ T cell programme that collapses hair follicle immune privilege and causes diffuse scalp hair loss in alopecia areata. The originator brand for ritlecitinib is LITFULO® (Pfizer, FDA-approved June 2023). LuciRit, manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is available through Mediaid Pharmacy with worldwide shipping to patients, alopecia areata specialist centres, and dermatology clinics.
What is the generic name of LuciRit?
The generic name of LuciRit is ritlecitinib INN. LuciRit is the brand name registered by Lucius Pharmaceuticals (Lao) Co., Ltd. for ritlecitinib manufactured in Laos. LuciRit is formulated as oral capsules in 50 mg strength, supplied in a 28-capsule pack corresponding to four weeks of the approved once-daily fixed-dose regimen with no dose titration required. The originator reference brand is LITFULO® (Pfizer). Mediaid Pharmacy distributes LuciRit globally with worldwide shipping to patients, dermatology centres, alopecia areata clinics, and hospital pharmacy departments.
What is the difference between LuciRit (Ritlecitinib) and LITFULO (Ritlecitinib)?
LuciRit and LITFULO® both contain ritlecitinib INN as the active pharmaceutical ingredient and share the same first-in-class selective irreversible covalent JAK3/TEC family kinase inhibitor mechanism of action in severe alopecia areata. LITFULO® is the originator brand developed and marketed by Pfizer, approved by the FDA in June 2023 in the 50 mg capsule strength for adults and adolescents 12 years and older with severe alopecia areata; additional regulatory approvals have been granted in subsequent years. LuciRit is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied in the 50 mg capsule strength the sole approved therapeutic dose in a 28-capsule pack, available through Mediaid Pharmacy for international procurement by specialist alopecia areata centres and patients in regions where LITFULO® may be unavailable or cost-prohibitive. For the full range of dermatology medicines at Mediaid Pharmacy, visit the Mediaid Pharmacy dermatology medicines collection.
How is LuciRit 50 MG (Ritlecitinib) administered?
LuciRit (Ritlecitinib) is administered orally once daily at the same time each day, with or without food. The dose is 50 mg once daily no titration is needed. Swallow LuciRit capsules whole with water do not open, crush, or chew. If a dose is missed, take it as soon as remembered on the same day; if not remembered until the next day, skip the missed dose and continue with the next scheduled dose. Do not take two doses in one day. Do not abruptly discontinue LuciRit without consulting the treating dermatologist, as alopecia areata hair loss may recur following cessation of JAK3/TEC inhibitor therapy.
What are the side effects of LuciRit 50 MG (Ritlecitinib)?
The most commonly reported adverse reactions of ritlecitinib in the ALLEGRO Phase 2b/3 trial include headache, diarrhea, acne, rash, urticaria, elevated creatine phosphokinase (CPK), nausea, folliculitis, and upper respiratory tract infection. Most adverse reactions were mild-to-moderate in severity and did not require treatment discontinuation. Ritlecitinib carries a boxed warning for serious infections, malignancy, major adverse cardiovascular events (MACE), and thrombosis consistent with the JAK inhibitor drug class though the clinical trial programme for severe alopecia areata did not report high rates of these events. TB screening before initiation and avoidance of live vaccines during treatment are required. Always discuss the complete safety profile, infection risk, vaccination status, pregnancy risk, cardiovascular risk, and drug interaction potential with the treating dermatologist before and throughout LuciRit treatment.
How effective is Ritlecitinib (LuciRit) for severe alopecia areata?
Ritlecitinib has demonstrated statistically significant and clinically meaningful efficacy in severe alopecia areata in the Phase 2b/3 ALLEGRO trial (718 randomised patients). Ritlecitinib 50 mg once daily achieved SALT score of 20 or below (at least 80% scalp hair coverage) in 23.0% of patients versus 1.6% placebo at Week 24 (p<0.001), with a subset of patients achieving SALT score of 10 or below (90% or greater scalp hair coverage) and meaningful regrowth in eyebrows and eyelashes. Hair regrowth response continued to improve through Week 48 in patients maintained on continuous ritlecitinib 50 mg, with no new safety signals identified on longer-term follow-up. LuciRit delivers the same active ingredient ritlecitinib INN at the approved 50 mg once-daily capsule dose, sourced through Mediaid Pharmacy with worldwide shipping. For the complete dermatology medicines range at Mediaid Pharmacy, browse the full portfolio.
Is LuciRit 50 MG (Ritlecitinib) safe during pregnancy or while breastfeeding?
LuciRit (Ritlecitinib) is not recommended during pregnancy, as ritlecitinib may cause fetal harm based on animal reproductive toxicity studies. Females of reproductive potential must use effective contraception during LuciRit treatment and for the recommended period after the final dose. A pregnancy test must be performed before initiating LuciRit treatment. Breastfeeding is not recommended during LuciRit treatment because of the potential for serious adverse reactions in the breastfed infant. If pregnancy occurs during ritlecitinib treatment, the treating dermatologist must be notified immediately. Consult the treating specialist before starting LuciRit in any patient of reproductive potential and review the current prescribing information for the most up-to-date reproductive safety guidance.
Can I order LuciRit 50 MG (Ritlecitinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies LuciRit 50 MG (Ritlecitinib) to patients, dermatology clinics, alopecia areata specialist centres, hair loss specialist units, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order LuciRit 50 MG (Ritlecitinib) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.